Cadrenal Therapeutics, Inc. Research and Development Expense
Cadrenal Therapeutics, Inc. (CVKD) reported Research and Development Expense of $705.15 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $705.15K, a 34.56% decline year-over-year.
- Cadrenal Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $771.51K, a 53.74% decline year-over-year.
- Cadrenal Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $666.32K, a 56.67% decline year-over-year.
- Cadrenal Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $688.47K, a 12.26% decline year-over-year.
- Cadrenal Therapeutics, Inc. research and development expense for fiscal 2025 was $4.10M, a 2.49% decline from fiscal 2024.
- Cadrenal Therapeutics, Inc. research and development expense for fiscal 2024 was $4.21M, a 3.03% increase from fiscal 2023.
- Cadrenal Therapeutics, Inc. research and development expense for fiscal 2023 was $4.08M.
| Period end | Research and Development Expense 0 month | Research and Development Expense | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 8 month | Research and Development Expense 9 month | Research and Development Expense 11 month | Research and Development Expense 11 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $705.15K 10-Q · filed 2026-08-13 | $1.48M 10-Q · filed 2026-08-13 | $2.14M derived: sum of 3 quarters · filed 2026-08-13 | $2.83M derived: sum of 4 quarters · filed 2026-08-13 | |||||||
| 2026-03-31 | $771.51K 10-Q · filed 2026-05-07 | $1.44M derived: sum of 2 quarters · filed 2026-05-07 | $2.13M derived: sum of 3 quarters · filed 2026-05-07 | $3.20M derived: sum of 4 quarters · filed 2026-08-13 | |||||||
| 2025-12-31 | $666.32K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.35M derived: sum of 2 quarters · filed 2026-03-31 | $2.43M derived: sum of 3 quarters · filed 2026-08-13 | $4.10M 10-K · filed 2026-03-31 | |||||||
| 2025-09-30 | $688.47K 10-Q · filed 2025-11-10 | $1.77M derived: sum of 2 quarters · filed 2026-08-13 | $3.43M 10-Q · filed 2025-11-10 | $4.97M derived: sum of 4 quarters · filed 2026-08-13 | |||||||
| 2025-06-30 | $1.08M 10-Q · filed 2026-08-13 | $2.75M 10-Q · filed 2026-08-13 | $4.28M derived: sum of 3 quarters · filed 2026-08-13 | $5.07M derived: sum of 4 quarters · filed 2026-08-13 | |||||||
| 2025-03-31 | $1.67M 10-Q · filed 2026-05-07 | $3.21M derived: sum of 2 quarters · filed 2026-05-07 | $3.99M derived: sum of 3 quarters · filed 2026-05-07 | $5.24M derived: sum of 4 quarters · filed 2026-05-07 | |||||||
| 2024-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.32M derived: sum of 2 quarters · filed 2026-03-31 | $3.58M derived: sum of 3 quarters · filed 2026-03-31 | $4.21M 10-K · filed 2026-03-31 | |||||||
| 2024-09-30 | $784.65K 10-Q · filed 2025-11-10 | $2.04M derived: sum of 2 quarters · filed 2025-11-10 | $2.67M 10-Q · filed 2025-11-10 | $3.03M derived: sum of 4 quarters · filed 2025-11-10 | |||||||
| 2024-06-30 | $1.25M 10-Q · filed 2025-08-11 | $1.88M 10-Q · filed 2025-08-11 | $2.24M derived: sum of 3 quarters · filed 2025-08-11 | $2.49M derived: sum of 4 quarters · filed 2025-08-11 | |||||||
| 2024-03-31 | $629.02K 10-Q · filed 2025-05-08 | $990.15K derived: sum of 2 quarters · filed 2025-05-08 | $1.23M derived: sum of 3 quarters · filed 2025-05-08 | $1.48M derived: sum of 4 quarters · filed 2025-05-08 | |||||||
| 2023-12-31 | $361.13K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $605.08K derived: sum of 2 quarters · filed 2025-03-13 | $846.03K derived: sum of 3 quarters · filed 2025-03-13 | $4.08M 10-K · filed 2025-03-13 | |||||||
| 2023-09-30 | $243.95K 10-Q · filed 2024-11-07 | $484.90K derived: sum of 2 quarters · filed 2024-11-07 | $3.72M 10-Q · filed 2024-11-07 | ||||||||
| 2023-06-30 | $240.96K 10-Q · filed 2024-08-07 | $93.28K 10-Q · filed 2023-08-10 | $3.48M 10-Q · filed 2024-08-07 | $185.54K 10-Q · filed 2023-08-10 | |||||||
| 2023-03-31 | $3.24M 10-Q · filed 2024-05-09 | $92.26K 10-Q · filed 2023-05-10 | |||||||||
| 2023-01-19 | $3.00M 10-Q · filed 2024-11-07 | $3.00M 10-K · filed 2025-03-13 | |||||||||
| 2022-12-31 | $392.86K 10-K · filed 2024-03-11 | $136.80K 10-K · filed 2023-03-30 | |||||||||
| 2022-09-30 | $56.39K 10-Q · filed 2023-11-09 | $276.48K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |